Amino Nitrogen Attached To Aryl Ring Or Aryl Ring System By An Acyclic Carbon Or Acyclic Chain Patents (Class 514/649)
  • Patent number: 11986507
    Abstract: A micronutrient composition shown as Mix 1 comprises Rosemary extract at 1 mg-6,000 mg, Fenugreek extract 1 mg-50,000 mg and Fenugreek seed powder at 2 mg-8,000 mg, Cassia nomane seed extract powder 1 mg to 1,000 mg and dry extract 1 mg-300 mg, 3?3-di indolylmethylene 1 mg-800 mg, Zinc 0.1 mg-1,000 mg, Phosphatidylserine 1 mg-1,500 mg, Vitamin D 20 IU-10,000 IU, Vitamin C 10 mg-50,000 mg, Niacin 1 mg-3,000 mg, Theanine 0.1 mg-10,000 mg, Aspartic acid 10 mg-10,000 mg, Arginine 10 mg-50,000 mg and Dehydroepiandrosterone (DHEA) 1 mg-500 mg and Mix A comprising of all the ingredients of Mix 1 but does not contain DHEA and both are used improve men's health.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: May 21, 2024
    Inventor: Matthias W Rath
  • Patent number: 11857569
    Abstract: A saline nasal cleansing solution comprising: a water component; a humectant component; a salt component; a cleansing component; a surfactant component; a gelling component; a preservative component; an antioxidant component; and one or more natural extracts; wherein the cleansing component is ppg-26-butanol polyether-26; wherein the humectant component is sorbitol; wherein the salt component is sodium chloride; wherein the surfactant component is PEG-40 hydrogenated castor oil.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: January 2, 2024
    Assignee: Joonem LLC
    Inventors: Eyal Termechi, Asaf Azaria
  • Patent number: 11759420
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: September 19, 2023
    Assignee: CRYSTEC LTD
    Inventors: Daniel Mark Ledger, Linda Sharon Daintree, Peter York
  • Patent number: 11759439
    Abstract: The invention relates to bromhexine or a salt thereof for treating acute or chronic pain in a patient. In particular, the invention relates to bromhexine or a salt thereof for use in treating nociceptive pain, neuropathic pain and or dysfunctional pain. The invention further relates to a topical pharmaceutical composition comprising bromhexine or a salt thereof and to a composition or a topical pharmaceutical composition comprising bromhexine or a salt thereof for treating acute or chronic pain.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: September 19, 2023
    Inventor: Kai-Uwe Kern
  • Patent number: 11759620
    Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: September 19, 2023
    Assignee: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
    Inventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
  • Patent number: 11712448
    Abstract: The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 1, 2023
    Assignee: ALGIPHARMA AS
    Inventors: Arne Dessen, Philip Rye
  • Patent number: 11633370
    Abstract: Methods and compounds for use in promoting survival of at least one eukaryotic cell, wherein the compounds are effective as gamma-ketoaldehyde scavengers.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 25, 2023
    Assignee: Vanderbilt University
    Inventors: L. Jackson Roberts, II, Thuy T. Nguyen
  • Patent number: 11583508
    Abstract: Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 21, 2023
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Chunlei Li, Yueying Peng, Kun Lou, Yajuan Wang, Yumei Wang, Shan Chen, Zhibin Meng, Jianfei Xue, Jing Yuan, Hongmei Luo, Xuekun Yao, Shixia Wang
  • Patent number: 11548847
    Abstract: Provided are a novel amine composition and a novel amine compound. Also provided are a method for producing the amine composition and amine compound, and an epoxy resin curing agent, an epoxy resin composition, a cured product, a urethane prepolymer curing agent, a polyurethane urea resin composition, a polyamide varnish, and a polyamide, each obtained using the amine composition and amine compound. The amine composition contains a compound represented by Formula (1), wherein A is a cyclic alkylene group, and B is a group containing an aryl group or a heteroaryl group.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 10, 2023
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventor: Yuiga Asai
  • Patent number: 11529344
    Abstract: This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: December 20, 2022
    Assignee: Pfizer Inc.
    Inventors: Manfred Kraus, Pei-Pei Kung, Thomas Andrew Paul, Shikhar Sharma, Dominique Verhelle
  • Patent number: 11491151
    Abstract: A stable liquid composition contained in a bottle wherein the composition comprises from about 0.001% to about 0.5% of phenylephrine hydrochloride, by weight of the stable liquid composition. The composition comprises less than about 0.1% of total aldehydes, by weight of the stable liquid composition, and has a pH from about 2 to about 6.5. The bottle comprises a material selected from polyethylene terephthalate (PET), glycol-modified polyethylene terephthalate (PETG), oriented polypropylene (OPP), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), nylon, polyethylene terephthalate polyester (PETP), or combinations thereof.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: November 8, 2022
    Assignee: THE PROCTER & GAMBLE COMPANY
    Inventors: Kelly Lee Martin Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines, Thomas Edward Huetter, Radhika R. Iyer, Daren K. Anness
  • Patent number: 11344513
    Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: May 31, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11344514
    Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: May 31, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11331285
    Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: May 17, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11246830
    Abstract: The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: February 15, 2022
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Shinya Matsumura, Toshihiro Nakanishi, Yasuhisa Kose
  • Patent number: 11219601
    Abstract: The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 11, 2022
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Shinya Matsumura, Toshihiro Nakanishi, Yasuhisa Kose
  • Patent number: 11185588
    Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 30, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
  • Patent number: 11179352
    Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: November 23, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11179351
    Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: November 23, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11141415
    Abstract: A stable liquid composition in a clear bottle where the composition contains, at least, phenylephrine and acetaminophen. The composition is substantially free of aldehydes and has a pH from 3.5 to 5. The clear bottle is a polyethylene terphthalate bottle.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: October 12, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Kelly Lee Martin Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines, Thomas Edward Huetter, Radhika R. Iyer, Daren K. Anness
  • Patent number: 11083697
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 10, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
  • Patent number: 11065210
    Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: 10XBIO, LLC
    Inventor: John Daniel Dobak, III
  • Patent number: 11044909
    Abstract: The present disclosure relates to a composition for the destruction of microalgae or mosses. The composition for the destruction of microalgae or mosses may suppress the growth and proliferation of microalgae when treated in moss cultivation facilities, marine microalgae cultivation facilities, areas in which green or red tide is occurring, or areas in which green or red tide is expected to occur, thereby preventing damage caused by the green or red tide.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 29, 2021
    Assignee: CUREARTH, INC.
    Inventors: Hoon Cho, Sun Jong Yu, Seung Ho Baek, Hyung Joon Cha
  • Patent number: 10987370
    Abstract: Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: April 27, 2021
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Rina Rosin-Arbesfeld, Michal Caspi, Dalia Megiddo
  • Patent number: 10919841
    Abstract: The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 16, 2021
    Assignee: Research Triangle Institute
    Inventors: Frank Ivy Carroll, Bruce Edward Blough, Philip Abraham
  • Patent number: 10806710
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 20, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10787421
    Abstract: The invention provides compounds formula (I) and salts thereof: wherein R1-R4 have any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: September 29, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Carl Wagner, Peter Jurutka, Pamela Marshall
  • Patent number: 10758500
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 1, 2020
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Patent number: 10710957
    Abstract: Motuporamine agents having antimicrobial activity and uses thereof.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 14, 2020
    Assignees: University of Central Florida Research Foundation, Inc., Inserm Transfert, S.A.
    Inventors: Otto Phanstiel, IV, Jean-Michel Brunel
  • Patent number: 10596261
    Abstract: The present invention provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises vinyl lactam derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared by a continuous process and has a Brookfield cohesion of less than 0.12 kPa, a bulk density of at least 0.249 gram/milliliter and a flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 24, 2020
    Inventors: Divya Tewari, Yevgeniya A. Titova, Brad Beissner, Thomas Durig
  • Patent number: 10588914
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: March 17, 2020
    Assignee: ENCORE DERMATOLOGY, INC.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 10568851
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: February 25, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Krzysztof Palczewski, Yu Chen
  • Patent number: 10543174
    Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: January 28, 2020
    Assignee: Synthon B.V.
    Inventors: Agnes Fernandez Pena, Jose Velada Calzada, Rohit Kumar, Lisardo Alvarez Fernandez
  • Patent number: 10485767
    Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: November 26, 2019
    Inventor: John Daniel Dobak, III
  • Patent number: 10463635
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: November 5, 2019
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Patent number: 10369144
    Abstract: The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 6, 2019
    Assignee: PureTech Health LLC
    Inventors: Eric Elenko, Philip E. Murray, III, Andrew C. Miller
  • Patent number: 10258598
    Abstract: The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumor manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 16, 2019
    Assignees: Semmelweis University, Fujimoto Co. Ltd.
    Inventors: József Knoll, Ildikó Miklya, Péter Ferdinandy, Dezso Schuler, Zsuzsanna Schaff, Sándor Eckhardt
  • Patent number: 10238643
    Abstract: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 26, 2019
    Assignee: PureTech Health LLC
    Inventors: Eric Elenko, Philip E. Murray, III, Andrew C. Miller
  • Patent number: 10207982
    Abstract: The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: February 19, 2019
    Assignee: Alparis, S.A. DE C.V.
    Inventors: Jorge Guillermo Domínguez Chávez, Karina Mondragón Vásquez, Hugo Morales Rojas, Dea Herrera Ruiz, Herbert Höpfl, Reyna Reyes Martínez, Javier Hernández Illescas, Juan Pablo Senosiain Peláez
  • Patent number: 10179137
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: January 15, 2019
    Assignee: PROMIUS PHARMA LLC
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 10166248
    Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one ?-KA scavenger compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: January 1, 2019
    Assignee: Vanderbilt University
    Inventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
  • Patent number: 10105375
    Abstract: Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 23, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum
  • Patent number: 10074170
    Abstract: A method of producing a tablet in which an uncoated tablet is coated by a coating agent, the method including: a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container, wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to the weight of the coating agent with which the uncoated tablets are coated, such that the humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: September 11, 2018
    Assignees: FUJI XEROX CO., LTD., Daiichi Sankyo Company, Limited
    Inventors: Kensuke Ito, Yasuhiro Suzuki
  • Patent number: 10064875
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: September 4, 2018
    Assignee: PROMIUS PHARMA LLC
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9987492
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 5, 2018
    Assignee: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Kevin J. Tracey, Jared M. Huston
  • Patent number: 9962372
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of benzydamine and an antimycotic active ingredient, said combination having a synergistic effect in the treatment of mycosis.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 8, 2018
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Claudio Milanese, Alessandra Capezzone De Joannon, Serena Tongiani, Luca Donati
  • Patent number: 9956231
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 1, 2018
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
  • Patent number: 9913847
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 13, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 9895360
    Abstract: Combination compositions and kits comprising an analgesic and an antihistamine are provided as well as methods of use in treating sunburn.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 20, 2018
    Assignee: Sephoris Pharmaceuticals, LLC
    Inventors: Talal Sheena, Melwyn Abreo
  • Patent number: 9877974
    Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: January 30, 2018
    Assignee: Dr. Reddy's Laboratories, Ltd.
    Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu